Significant infections after hand transplantation in a Polish population.
The study was conducted to assess serious infectious complications in five hand allograft recipients (four males, one female, age 40 ± 10 years), transplanted between 2006 and 2010. All donors and recipients were positive but one for cytomegalovirus (CMV) immunoglobulin G. All recipients received immunosuppressive therapy basiliximab, tacrolimus, mycophenolate mofetil and methylprednisolone. Until May 2013, there were four cases of severe infections requiring hospitalization. One patient developed CMV infection on the 28th postoperative day. Despite therapy with ganciclovir and prophylaxis with valganciclovir, reinfection episodes occurred both 4 weeks and 7 months later. The female recipient developed CMV infection 8 months after hand transplantation. After 3 weeks of ganciclovir treatment, the polymerase chain reaction results remained negative. We found that the CD4/CD8 T lymphocytes ratio differs in those two patients who had developed CMV disease in the past in comparison to the three remaining hand transplant recipients (mean 0.46 versus 1.7, respectively). Moreover, the ratio of patients who were CD4-8 negative to total T lymphocytes in CMV recovered patients was two-fold higher compared to the remaining recipients (10.0 versus 4.4, respectively). The female recipient was also hospitalized because of acute tonsillitis 25 months after hand transplantation, and successfully treated with amoxicillin clavulanate. The third recipient was hospitalized because of severe acute pain involving right lower limb, especially foot, 74 months after hand transplantation. After 48 hours, a painful vesicular rash occurred on the plantar as well as dorsal surface of right foot and herpes zoster was diagnosed. Immunosuppressive therapy after hand transplantation may be complicated by serious infections. CMV disease was associated with persistent alterations in T lymphocyte subsets.
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland. Electronic address: dorotakaminska@interia.pl.
D
D
Kamińska
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
K
K
Kościelska-Kasprzak
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
M
M
Myszka
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
M
M
Banasik
Subdepartment of Replantation of Limbs St. Hedwig District Hospital in Trzebnica, Trzebnica, Poland.
A
A
Chełmoński
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
M
M
Boratyńska
Subdepartment of Replantation of Limbs St. Hedwig District Hospital in Trzebnica, Trzebnica, Poland.
J
J
Jabłecki
Subdepartment of Replantation of Limbs St. Hedwig District Hospital in Trzebnica, Trzebnica, Poland.
M
M
Klinger
D000328:Adult; D064591:Allografts; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology*; D005260:Female; D063987:Hand Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011044:Poland; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D016176:T-Lymphocyte Subsets; D016559:Tacrolimus / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000009:adverse effects; D063986:Vascularized Composite Allotransplantation / Q000009:adverse effects*
D000998:Antiviral Agents; D016559:Tacrolimus